At a Glance
- Company: Incyte
- Target: Vega Therapeutics, a Star Therapeutics subsidiary
- Deal value: About $1.25 billion upfront
- Focus area: Bleeding disorders
- Next steps: Close the acquisition and advance the programme
What happened?
Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth about $1.25 billion upfront. The acquisition gives Incyte control of a programme focused on bleeding disorders.
Why does it matter?
The deal strengthens Incyte’s pipeline with an asset in a specialised haematology area that still has meaningful unmet need. Bleeding disorders can require long-term management, so new therapies with improved efficacy or convenience can have a strong clinical and commercial profile.
Who’s behind it?
Incyte is a US biopharmaceutical company best known for its work in oncology and inflammation. Vega Therapeutics operates as part of Star Therapeutics, which develops medicines for serious haematologic diseases.
How was it achieved?
The transaction is structured as an outright acquisition rather than a partnership or licensing deal, with Incyte paying roughly $1.25 billion upfront. That gives Incyte full ownership of the programme and its development path.
What’s next?
The companies will move toward closing the transaction and integrating the programme into Incyte’s research and development organisation. After that, the priority will be advancing the bleeding disorders asset through the next stages of development.